[go: up one dir, main page]

DE60030764D1 - Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten - Google Patents

Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten

Info

Publication number
DE60030764D1
DE60030764D1 DE60030764T DE60030764T DE60030764D1 DE 60030764 D1 DE60030764 D1 DE 60030764D1 DE 60030764 T DE60030764 T DE 60030764T DE 60030764 T DE60030764 T DE 60030764T DE 60030764 D1 DE60030764 D1 DE 60030764D1
Authority
DE
Germany
Prior art keywords
endothelin
sulfonamide
antagonists
biphenyl
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60030764T
Other languages
English (en)
Other versions
DE60030764T2 (de
Inventor
Natesan Murugesan
E Tellew
E Macor
Zhengxiang Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE60030764D1 publication Critical patent/DE60030764D1/de
Application granted granted Critical
Publication of DE60030764T2 publication Critical patent/DE60030764T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60030764T 1999-12-15 2000-12-13 Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten Expired - Fee Related DE60030764T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US481197 1990-02-20
US46403799A 1999-12-15 1999-12-15
US464037 1999-12-15
US48119700A 2000-01-11 2000-01-11
US51377900A 2000-02-25 2000-02-25
US513779 2000-02-25
US60432200A 2000-06-26 2000-06-26
US64364000A 2000-08-22 2000-08-22
US643640 2000-08-22
PCT/US2000/033730 WO2001044239A2 (en) 1999-12-15 2000-12-13 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US604322 2004-01-20

Publications (2)

Publication Number Publication Date
DE60030764D1 true DE60030764D1 (de) 2006-10-26
DE60030764T2 DE60030764T2 (de) 2007-09-13

Family

ID=27541688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030764T Expired - Fee Related DE60030764T2 (de) 1999-12-15 2000-12-13 Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten

Country Status (12)

Country Link
EP (2) EP1237888B1 (de)
JP (1) JP2003520785A (de)
AR (1) AR029417A1 (de)
AT (1) ATE339417T1 (de)
AU (1) AU2092601A (de)
CA (1) CA2395088A1 (de)
CO (1) CO5450242A1 (de)
DE (1) DE60030764T2 (de)
ES (1) ES2273739T3 (de)
PE (1) PE20010930A1 (de)
UY (1) UY26482A1 (de)
WO (1) WO2001044239A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
DK1395566T3 (da) 2001-05-31 2008-01-07 Vicore Pharma Ab Tricycliske forbindelser, der er nyttige som angiotensin Il-agonister
WO2003042174A1 (en) 2001-11-14 2003-05-22 Schering Corporation Cannabinoid receptor ligands
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
CA2487346A1 (en) 2002-06-19 2003-12-31 Schering Corporation Cannabinoid receptor agonists
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004085420A1 (en) * 2003-03-24 2004-10-07 Vicore Pharma Ab Bicyclic compounds useful as angiotensin ii agonists
JP2006525328A (ja) * 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法
DE10336497B4 (de) * 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
MX2008011227A (es) * 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
WO2007109456A2 (en) * 2006-03-16 2007-09-27 Pharmacopeia, Inc. Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
AU2012203919B2 (en) * 2006-03-20 2014-10-23 Novartis Ag Method of treatment or prophylaxis of inflammatory pain
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
WO2009155448A1 (en) * 2008-06-20 2009-12-23 Ligand Pharmaceuticals Inc. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2009158309A2 (en) * 2008-06-25 2009-12-30 Ligand Pharmaceuticals Inc. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
EP3708163A1 (de) 2009-03-31 2020-09-16 Ligand Pharmaceuticals, Inc. Verwendung von sparsentan zur behandlung von chronischen entzündlichen krankheiten
EP2451782B1 (de) * 2009-07-07 2016-11-09 Theravance Biopharma R&D IP, LLC Blutdrucksenkende mittel auf pyrazolbasis mit doppelwirkung
CN104761548B (zh) * 2015-04-27 2017-09-12 梯尔希（南京）药物研发有限公司 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法
US20190262317A1 (en) 2016-10-13 2019-08-29 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
EP3592730B1 (de) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs von sulfasalazin, pharmazeutische zusammensetzungen davon und deren verwendung in der behandlung von autoimmunkrankheiten
PL3630188T3 (pl) 2017-05-31 2022-01-03 Amplio Pharma Ab Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
US11365194B2 (en) * 2017-09-27 2022-06-21 Kagoshima University Analgesic drug using PAC1 receptor antagonistic drug
EP3489222A1 (de) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazinesalze, herstellungsverfahren und verwendungen
DK3488868T3 (da) 2017-11-23 2023-11-27 Medac Ges Fuer Klinische Spezialpraeparate Mbh Farmaceutisk sammensætning til oral indgivelse, som indeholder sulfasalazin og/eller et organisk sulfasalazinsalt, fremstillingsfremgangsmåde samt anvendelse
BR112021006132A2 (pt) 2018-10-04 2021-07-20 Travere Therapeutics, Inc. compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv
BR112021012226A2 (pt) * 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo
CN109928897B (zh) * 2019-04-01 2021-09-14 四川大学华西医院 防治梗死性疾病的双胍衍生物及其应用
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
MX2024002411A (es) * 2021-08-26 2024-04-05 Shanghai Hansoh Biomedical Co Ltd Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.
EP4421073A4 (de) * 2021-10-21 2025-02-26 Nicoya Therapeutics (Shanghai) Co., Ltd Dualer antagonisten und verwendung davon
CN118284605A (zh) * 2021-12-28 2024-07-02 亚克医药株式会社 化合物、血管紧张素ii第1型受体拮抗剂及医药组合物
CN115636799A (zh) * 2022-11-04 2023-01-24 苏州莱安医药化学技术有限公司 一种双效内皮素-血管紧张素受体拮抗剂的制备方法
AU2024224496A1 (en) * 2023-02-24 2025-10-02 Changzhou Hansoh Pharmaceutical Co., Ltd. Salt containing aromatic ring derivative antagonist, preparation method therefor, and application thereof
WO2025149789A1 (en) * 2024-01-09 2025-07-17 Procos S.P.A. Process for the preparation of sparsentan
CN120289447A (zh) * 2025-06-11 2025-07-11 成都臻拓医药科技有限公司 一种司帕生坦的晶型及其制备方法、药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260328A (en) * 1989-04-06 1993-11-09 Farmitalia Carlo Erba Srl Phenyl-indenopurazol 3-oxo-propanamide derivatives useful in the treatment of rheumatoid arthritis
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
GB2264710A (en) * 1992-03-04 1993-09-08 Merck & Co Inc Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5554625A (en) * 1992-07-17 1996-09-10 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
WO1997000256A1 (en) * 1995-06-15 1997-01-03 Merck & Co., Inc. Polymorphic forms of an angiotensin ii antagonist
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
IL140622A0 (en) * 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof

Also Published As

Publication number Publication date
EP1237888A2 (de) 2002-09-11
ATE339417T1 (de) 2006-10-15
AR029417A1 (es) 2003-06-25
ES2273739T3 (es) 2007-05-16
UY26482A1 (es) 2001-07-31
CO5450242A1 (es) 2004-10-29
DE60030764T2 (de) 2007-09-13
EP1237888B1 (de) 2006-09-13
JP2003520785A (ja) 2003-07-08
WO2001044239A3 (en) 2001-11-01
CA2395088A1 (en) 2001-06-21
PE20010930A1 (es) 2001-11-18
WO2001044239A2 (en) 2001-06-21
EP1741713A2 (de) 2007-01-10
AU2092601A (en) 2001-06-25
EP1741713A3 (de) 2009-09-09

Similar Documents

Publication Publication Date Title
ATE339417T1 (de) Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
DE60002992D1 (de) Dreiphasenabscheider
DE60005976D1 (de) Speicherkkarte
DE19983871T1 (de) Fönvorrichtung
DE60134094D1 (de) C7-taxanester als antitumormittel
DE60017513D1 (de) Spritzenendstückkappe
DE60001240D1 (de) Laserdepiliergerät
DE60020629D1 (de) Kassettengleitringdichtung
DE60009430D1 (de) Türtülle
DE60008638D1 (de) Förderbandabstreicher
DE69932949D1 (de) Aufszugssteuerung
DE60015794D1 (de) Kompositverschlusskappe
DE60017027D1 (de) Gehrungseinrichtung
DE60001894T2 (de) Busschienenverbindungsstruktur
DE50015451D1 (de) Spülwannensystem
DE60012576D1 (de) Spreizfaktorbestimmung
DE59910286D1 (de) Kniehebel-spannvorrichtung
DE60013054D1 (de) Reissverschlusszuglasche
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
DE69935066D1 (de) Befehlsvorausholeinheit
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE60033003D1 (de) Münzrollmaschine
DE60023130D1 (de) Scharnierarmbefestigung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee